Kymera Therapeutics (KYMR) Investor Presentation - Slideshow

HS (n=13) AD (n=8) Patients with any prior Therapy, n (%) Antibiotics/Antibacterials** Corticosteroids Adalimumab Other Biologics Patient Disposition Completed 12 • 9 Moderate • 1 Severe • 2 Very Severe * Withdrew treatment after 4 doses for personal reasons ** Withdrew treatment after 5 doses for personal reasons KT-474 PK at the 75 mg QD dose (fed state) in patients is comparable to 100 mg QD (fasted state) in HV IRAK4 Levels in PBMC in Patients at Day 28 (MS) AD Patients (Baseline) M ean ( ±SE) IRA K4 Le ...